
Opinion|Videos|January 9, 2025
OlympiA: Adj Olaparib Post (Neo) Adjuvant Chemo in Pts with Germline BRCA1/BRCA2 & High Risk HER2-negative
Panelists discuss the OlympiA trial, evaluating adjuvant olaparib post-neoadjuvant chemotherapy in patients with germline BRCA1/BRCA2 mutations and high-risk HER2-negative breast cancer, and its impact on treatment outcomes.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
Lung Cancer News Roundup: June 2026
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5









































